The web site logo

If a women tests positive for BRCA-1, she may get prophylactic bilateral mastectomies or start taking Tamoxifen prophylactically for the rest of her life.

In Nature 1993, Druker describes adding CGP57148 to leukemia cells from a human marrow in a petri dish.  He cured leukemia in the dish.

Ciba-Geigy did not want to spend $200 million on trials for a drug that would treat CML (Chronic Myeloid Leukemia), as this disease only afflicts only a few thousand people a year.

Druker persisted and by 1998 he witnessed dozens of remissions in CML  with this drug. It was then marketed as Gleevec.

As of 2009, author Siddhartha Mukherjee writes in his book, " The Emperor of all Maladies" , on page 440:

"As of 2009, CML patients treated with Gleevec survive an average of thirty years after their diagnosis.  Based on that survivial figure, Hagop Kantarjian estimates that within the next decade, 250,000 people will be living with CML in America, all of them on targeted therapy."

We can diagnosis atherosclerosis with a CAC of >1 or a CIMT at 1.0 mm or 75% tile.

Then we can treat it for $100 a year with generic statin and OTC niacin.

100,000 people a year die from sudden coronary death.  30 to 50% die with sudden coronary death as the first symptom.  Imagine the number of people alive 30 years from now based on a modest survival figure of 30,000 people a year saved from subclinical atherosclerosis.

Right now we have no program to find these people and treat them.

Yet CAC and CIMT is available at a reasonable price.

Lets do something!